Is Merck past Vioxx?
Merck stock surges 2.6% to 45.64 Oct. 20 on news that the firm is raising its 2006 earnings guidance. The closing marks the first time Merck's stock has closed above the level at which it was trading prior to the firm's withdrawal of the COX-2 inhibitor Vioxx (rofecoxib) in September 2004. Merck's market value has been buoyed over the last year by five new molecular entity approvals, most recently the type 2 diabetes therapy Januvia...
You may also be interested in...
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.